# Telmisartan + hydrochlorothiazide

**Indication**

<table>
<thead>
<tr>
<th>Essential hypertension</th>
<th>ICD11 code: BA00.Z</th>
</tr>
</thead>
</table>

**INN**

Telmisartan + hydrochlorothiazide

**Medicine type**

Chemical agent

**List type**

Core

**Formulations**

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

**EML status history**

First added in 2019 (TRS 1021)  
Changed in 2021

**Sex**

All

**Age**

Adolescents and adults

**Therapeutic alternatives**

Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for hydrochlorothiazide)

**Patent information**

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)  
Read more about patents.

**Wikipedia**

[Telmisartan + hydrochlorothiazide](https://en.wikipedia.org/wiki/Telmisartan)

**DrugBank**

[Telmisartan](https://www.drugbank.ca/drugs/DB00458),  
[Hydrochlorothiazide](https://www.drugbank.ca/drugs/DB00050)

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + hydrochlorothiazide on the EML.